Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $2

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) had its target price reduced by HC Wainwright from $210.00 to $200.00 in a report released on Monday morning, The Fly reports. HC Wainwright also issued estimates for Axsome Therapeutics’ Q1 2023 earnings at ($1.40) EPS, Q2 2023 earnings at ($1.40) EPS, Q3 2023 earnings at ($1.29) EPS, Q4 […]

Related Keywords

United States , America , Piper Sandler , Axsome Therapeutics Company Profile , Axsome Therapeutics Inc , Brinker Capital Investments , Health Sciences , Tower Research Capital , Axsome Therapeutics , Get Rating , Moderate Buy , Therapeutics Trading Down , Capital Investments , Research Capital , Products Overview , Pipeline Overview , Axsome Therapeutics Daily , Nasdaq Axsm , Axsm , Medical , Lower Price Target , Hc Wainwright ,